Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker Response
Dana-Farber Cancer InstituteScientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.